Reduced p16 Expression Correlates with Lymphatic Invasion in Colorectal Cancers

Hepato-Gastroenterology

Volumn 50, Issue 54, 2003, Pages 1756-1760

  Tada, Tomohiro ^a,b   Watanabe, Toshiaki ^a   Kazama, Shinsuke ^a   Kanazawa, Takamitsu ^a   Hata, Keisuke ^a   Komuro, Yasuhiro ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adenoma; Carcinoma in adenoma; Colorectal cancer; Hyperplastic polyp; Immunohistochemistry; p16; Prognosis

Indexed keywords

PROTEIN P16;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CELL DIFFERENTIATION; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECTUM;

EID: 0345393069     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707.
2. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-756.
3. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91:11045-11049.
4. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P: Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001; 81:217-229.
5. Trzeciak L, Hennig E, Kolodziejski J, Nowacki M, Ostrowski J: Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa. Cancer Lett 2001; 163:17-23.
6. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-4530.
7. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55:4531-4535.
8. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J, Biankin AV: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002; 122:1113-1121.
9. Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ: Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer 2000; 87:236-240.
10. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H: p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999; 116:394-400.
11. Matsubayashi H, Watanabe H, Nishikura K, Ajioka Y, Maejima T, Kijima H, Saitoh T: Advantages of immunostaining over DNA analysis using PCR amplification to detect p53 abnormality in long-term formalin-fixed tissues of human colorectal carcinomas. J Gastroenterol 1998; 33:662-669.
12. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, Enders GH: p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000; 119:929-942.
13. Milde-Langosch K, Ocon E, Becker G, Loning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998; 79:61-65.
14. Garcia JF, Villuendas R, Algara P, Saez AI, Sanchez-Verde L, Martinez-Montero JC, Martinez P, Piris MA: Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest 1999; 79:1453-1459.
15. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M: Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997; 3:2229-2236.
16. Kawabuchi B, Moriyama S, Hironaka M, Fujii T, Koike M, Moriyama H, Nishimura Y, Mizuno S, Fukayama M: p16 inactivation in small-sized lung adenocarcinoma its association with poor prognosis. Int J Cancer 1999; 84:49-53.
17. Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6:1845-1853.
18. Taga S, Osaki T, Ohgami A, Imoto H, Yoshimatsu T, Yoshino I, Yano K, Nakanishi R, Ichiyoshi Y, Yasumoto K: Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 1997; 80:389-395.
19. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R: Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol 2000; 157:1947-1953.
20. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T: Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74:255-259.
21. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999; 5:977-983.
22. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL: p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 2001; 7:3481-3490.
23. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL: Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001; 7:544-550.
24. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92:276-284.